Recent news on Prochieve

Columbia Laboratories (CBRX) Said PROCHIEVE Study Suggest an ...  -  Apr 26, 2007
StreetInsider.com (subscription),Data from the study show a delay in cervical shortening in patients treated with PROCHIEVE 8%, and suggest a correlation between the cervical length data,

UPDATE 1-Columbia Labs shares up after data suggests new finding  -  Apr 26, 2007
ReutersIn February, Columbia said it was dropping development of the gel, Prochieve, after a late-stage trial failed to meet its goal of reducing the rate of

StreetInsider.com Pre-Open Movers 04/26  -  Apr 26, 2007
StreetInsider.com (subscription),Columbia Laboratories Inc. (Nasdaq: CBRX) 39% HIGHER; Data on PROCHIEVE Suggest an Effect on Delaying Cervical Shortening.

Market Report -- In Play (CBRX)  -  26 Apr 2007
MSN MoneyColumbia Labs reports preliminary findings from the data analysis of the Phase III clinical study of Prochieve 8% to prevent preterm birth Co announces that

Columbia Laboratories to Discuss Infertility Business Outlook and ...  -  Feb 26, 2007
PharmaLive.com (press release),...the following: the successful marketing of CRINONE(R) 8% (progesterone gel), PROCHIEVE(R) 8%(progesterone gel), PROCHIEVE 4% (progesterone gel),

Columbia Laboratories Reports Fourth Quarter and Year-End 2006 ...  -  Mar 15, 2007
Genetic Engineering News (press release),Selling and distribution costs reflected marketing activities to prepare for the potential launch of PROCHIEVE(R) 8% (progesterone gel) for preterm birth

Phase III Trial of Progesterone for the Prevention of Preterm ...  -  Feb 5, 2007
PharmaLive.com (press release),Of the 611 evaluable patients in this randomized, placebo-controlled, double blind clinical trial, 302 received placebo and 309 received PROCHIEVE(R) 8%

UPDATE 1-Columbia Labs shares crash as gel trial fails  -  Feb 5, 2007
ReutersO: Quote, Profile , Research) said it was dropping development of its progesterone gel, Prochieve, to prevent preterm births after a late-stage trial failed

Columbia Laboratories’ Shares Plunge 65% on Phase III Failure  -  Feb 5, 2007
Genetic Engineering News (press release),Prochieve did not achieve any reduction in the incidence of preterm birth at week 32, the primary endpoint, or at weeks 28, 35, and 37, secondary endpoints

Columbia Shares Plunge on Drug Results  -  Feb 5, 2007
Forbes,In the study, 611 patients who previously had a preterm birth earlier than their 35th week of pregnancy received either the drug, also called Prochieve,

Market Report -- In Play (CBRX)  -  Feb 5, 2007
MSN MoneyThe incidence and profile of adverse events in patients receiving PROCHIEVE 8% was similar to placebo, which was as expected given the product's documented

Roth 2007 OC Conference Presenter Profiles  -  Feb 16, 2007
American Digital Networks (press release),Columbia markets PROCHIEVE(R) 8% (progesterone gel) for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile

Columbia Laboratories Completes Treatment Phase of Phase III Study ...  -  Dec 22, 2006
American Digital Networks (press release),The ultimate goal of this program is to expand the PROCHIEVE 8% label beyond infertility and secondary amenorrhea, for which it is currently FDA-approved

Columbia Laboratories (CBRX) Finishes Treatment Phase of PROCHIEVE ...  -  Dec 22, 2006
StreetInsider.com (subscription),Columbia Laboratories, Inc. (NASDAQ: CBRX) announced it has completed the treatment phase of its pivotal Phase III clinical study of PROCHIEVE 8%

Columbia Laboratories Completes Prochieve Clinical Trial  -  Dec 22, 2006
Business New Jersey (subscription),The gel, Prochieve 8%, which contains 90 mg of natural progesterone, is currently FDA-approved as an infertility treatment.

Columbia Laboratories Closes $40 Million Private Placement of ...  -  Dec 26, 2006
Genetic Engineering News (press release),..."The CRINONE acquisition also eliminates the 30% royalty we paid Serono on sales of PROCHIEVE(R) progesterone gel, and brings our gross margin for that

Columbia Laboratories to Raise $40 Million Through Private ...  -  Dec 22, 2006
American Digital Networks (press release),Columbia markets PROCHIEVE(R) 8% (progesterone gel) for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile

Market Report -- In Play (CBRX)  -  Dec 22, 2006
MSN MoneyColumbia Labs announced it has completed the treatment phase of its pivotal Phase III clinical study of Prochieve 8% Co announced it has completed the

Friday's Health Winners & Losers  -  Dec 22, 2006
TheStreet.comThe phase III trial involved Prochieve, a drug intended to prevent preterm births. Phase III is the stage of trials conducted just before a drug is reviewed

Columbia Laboratories Closes $40 Million Private Placement of ...  -  26 Dec 2006
Business Wire (press release),...“The CRINONE acquisition also eliminates the 30% royalty we paid Serono on sales of PROCHIEVE ® progesterone gel, and brings our gross margin for that ...

Columbia Laboratories (CBRX) Finishes Treatment Phase of PROCHIEVE ...  -  Dec 22, 2006
StreetInsider.com (subscription),Columbia Laboratories, Inc. (NASDAQ: CBRX) announced it has completed the treatment phase of its pivotal Phase III clinical study of PROCHIEVE 8% (progesterone ...

Columbia Laboratories Completes Prochieve Clinical Trial  -  Dec 22, 2006
Business New Jersey (subscription),...company. The gel, Prochieve 8%, which contains 90 mg of natural progesterone, is currently FDA-approved as an infertility treatment. ...

CORRECTING and REPLACING Columbia Laboratories Completes Treatment ...  -  Dec 22, 2006
Genetic Engineering News (press release),Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced it has completed the treatment phase of its pivotal Phase III clinical study of PROCHIEVE(R) 8 ...

Columbia Laboratories Completes Treatment Phase of Phase III Study ...  -  Dec 22, 2006
Business Wire (press release),...(NASDAQ: CBRX) today announced it has completed the treatment phase of its pivotal Phase III clinical study of PROCHIEVE ® 8% (progesterone gel) to prevent ...

Columbia Laboratories to Raise $40 Million Through Private ...  -  Dec 22, 2006
Genetic Engineering News (press release),...bear interest at a rate of 8% per annum that is reduced to 5% per annum if and when the Company receives approval for a label indication for PROCHIEVE(R) 8 ...

Market Report -- In Play (CBRX)  -  Dec 22, 2006
MSN MoneyColumbia Labs announced it has completed the treatment phase of its pivotal Phase III clinical study of Prochieve 8% Co announced it has completed the ...

James Meer Appointed Chief Financial Officer of Columbia ...  -  Dec 7, 2006
PharmaLive.com (press release),Columbia markets PROCHIEVE(R) 8% (progesterone gel) for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile ...

Friday's Health Winners & Losers  -  Dec 22, 2006
TheStreet.com...of a late-stage study. The phase III trial involved Prochieve, a drug intended to prevent preterm births. Phase III is the stage ...

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional